featured
Safety and Effectiveness of Weekly Combination Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab for Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial
JAMA Oncol 2021 Apr 15;[EPub Ahead of Print], O Landgren, M Hultcrantz, B Diamond, AM Lesokhin, S Mailankody, H Hassoun, C Tan, UA Shah, SX Lu, M Salcedo, K Werner, J Rispoli, J Caple, A Sams, D Verducci, K Jones, I Concepcion, A Ciardello, A Chansakul, J Schlossman, E Tavitian, T Shekarkhand, A Harrison, C Piacentini, EH Rustad, V Yellapantula, K Maclaughlan, F Maura, HJ Landau, M Scordo, DJ Chung, G Shah, OB Lahoud, K Thoren, K Murata, L Ramanathan, ME Arcila, C Ho, M Roshal, A Dogan, A Derkach, SA Giralt, N KordeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.